STOCK TITAN

Liquidia to Report First Quarter 2022 Financial Results on May 12, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Liquidia Corporation (NASDAQ: LQDA) will report its first quarter 2022 financial results on May 12, 2022. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a corporate update. Investors can access the call by dialing 1-877-707-8711 domestically or 1-857-270-6219 internationally, using conference code 4798065. The webcast will be archived for 30 days. Liquidia focuses on pulmonary hypertension treatments using its PRINT® Technology and has developed YUTREPIA™ for pulmonary arterial hypertension.

Positive
  • Scheduled release of Q1 2022 financial results may indicate transparency.
  • Company has developed a product (YUTREPIA™) targeting pulmonary hypertension.
Negative
  • None.

MORRISVILLE, N.C., May 05, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its first quarter 2022 financial results on Thursday, May 12, 2022. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update.

The live call may be accessed by dialing 1-877-707-8711 (domestic) or 1-857-270-6219 (international) and entering the conference code: 4798065. A webcast of the call will be available and archived for 30 days on Liquidia’s website at https://liquidia.com/index.php/investors/events-and-presentations.

About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH). Liquidia PAH provides the commercialization for rare disease pharmaceutical products, such as generic Treprostinil Injection. For more information, please visit www.liquidia.com.

Contact Information for Media & Investors
Jason Adair
Senior Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com 


FAQ

When will Liquidia Corporation report its Q1 2022 financial results?

Liquidia Corporation will report its Q1 2022 financial results on May 12, 2022.

What time is the Liquidia Corporation earnings call?

The earnings call for Liquidia Corporation will be held at 8:30 a.m. Eastern Time on May 12, 2022.

How can I access the Liquidia Corporation conference call?

You can access the conference call by calling 1-877-707-8711 domestically or 1-857-270-6219 internationally, using conference code 4798065.

What product has Liquidia Corporation developed for pulmonary hypertension?

Liquidia Corporation has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension.

Liquidia Corporation

NASDAQ:LQDA

LQDA Rankings

LQDA Latest News

LQDA Stock Data

912.38M
60.46M
19.49%
54.31%
12.25%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
MORRISVILLE